Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Visit One News Page for Italy news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Italy news headlines.

older | 1 | .... | 1053 | 1054 | (Page 1055) | 1056 | 1057 | .... | 1077 | newer

    0 0

    Dublin, Nov. 08, 2018 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024" report has been added to *ResearchAndMarkets.com's* offering.The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.

    The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market.

    However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.

    Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.

    Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and the Asia Pacific region. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to the development of bioinformatics.

    Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for the growth of this market.*Key Topics Covered**1. Introduction*
    1.1. Market Definition
    1.2. Market Segmentation
    1.3. Currency and Limitations
    1.3.1. Currency
    1.3.2. Limitations
    1.4. Key Stakeholders

    *2. Research Methodology*
    2.1. Research Process
    2.1.1. Secondary Research
    2.1.2. Primary Research
    2.1.3. Market Size Estimation

    *3. Executive Summary*
    3.1. Introduction
    3.2. Market Dynamics
    3.3. Product Segment Analysis
    3.4. Application Segment Analysis
    3.5. End User Analysis
    3.6. Regional Analysis
    3.7. Competitive Analysis

    *4. Market Overview*
    4.1. Introduction
    4.2. Drivers
    4.2.1. Rising Cancer Incidence
    4.2.2. Growing Adoption of Immunotherapy over other Treatment Options
    4.2.3. Increasing Number of Technological Collaborations and Mergers
    4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
    4.3. Market Restraints
    4.3.1. High Cost of Treatment
    4.4. Market Opportunities
    4.4.1. Growing R&D Expenditure
    4.4.2. High Growth Prospects in Emerging Economies
    4.5. Market Challenges
    4.5.1. Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
    4.5.2. Complexities of Tumor

    *5. Industry Insights*
    5.1. Key Industry Trends
    5.1.1. Personalized Immunotherapy
    5.1.2. Implementation of Next-Generation Sequencing Technologies
    5.1.3. Immunotherapy Combination
    5.1.4. Accelerated Approval
    5.1.5. China's Rapidly Expanding Cancer Immunotherapy Market
    5.2. Evolution of Cancer Immunotherapy
    5.3. Opdivo and Keytruda: Major Products in Cancer Immunotherapy Market

    *6. Cancer Immunotherapy Market, by Type*
    6.1. Introduction
    6.2. Monoclonal Antibodies
    6.3. Checkpoint Inhibitors
    6.4. Immunomodulators
    6.5. Vaccines
    6.6. Cell Therapies

    *7. Cancer Immunotherapy Market, by Application*
    7.1. Introduction
    7.2. Lung Cancer
    7.3. Breast Cancer
    7.4. Colorectal Cancer
    7.5. Melanoma
    7.6. Prostate Cancer
    7.7. Multiple Myeloma
    7.8. Other Cancer Types

    *8. Cancer Immunotherapy Market, by End User*
    8.1. Overview
    8.2. Hospitals
    8.3. Clinics and Others

    *9. Cancer Immunotherapy Market, by Region*
    9.1. Introduction
    9.2. North America
    9.2.1. U.S.
    9.2.2. Canada
    9.3. Europe
    9.3.1. Germany
    9.3.2. France
    9.3.3. U.K.
    9.3.4. Italy
    9.3.5. Spain
    9.3.6. Rest of Europe
    9.4. Asia Pacific
    9.4.1. China
    9.4.2. Japan
    9.4.3. India
    9.4.4. Rest of Asia Pacific
    9.5. Latin America
    9.6. Middle East & Africa

    *10. Competitive Landscape*
    10.1. Introduction
    10.2. Market Share Analysis
    10.3. Competitor Benchmarking
    10.4. Competitive Situation and Trends
    10.4.1. Approvals
    10.4.2. Agreements and Collaborations
    10.4.3. Acquisitions
    10.4.4. Other Developments

    *11. Company Profiles*
    11.1. Astrazeneca
    11.2. Amgen
    11.3. Bristol-Myers Squibb
    11.4. Eli Lilly
    11.5. Johnson & Johnson
    11.6. Merck & Co., Inc.
    11.7. Novartis International AG
    11.8. Pfizer Inc.
    11.9. F. Hoffmann-La Roche
    11.10. Celgene CorporationFor more information about this report visit https://www.researchandmarkets.com/research/7cgsnc/global_cancer?w=12

    CONTACT:
    CONTACT: ResearchAndMarkets.com
    Laura Wood, Senior Press Manager
    press@researchandmarkets.com
    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900
    Related Topics: Genomics, Immune Disorders Drugs, Biopharmaceuticals , Hematology , Cancer Vaccines, Immunosuppressive Drugs Reported by GlobeNewswire 2 hours ago.

    0 0

    Valencia who briefly occupied second spot, are third on five points ahead of their own trip to Italy later this month.  Reported by Zee News 1 hour ago.

    0 0

    Xiaomi launches in the UK with Mi 8 Pro flagship Xiaomi’s international expansion is taking a major step forward today with the Chinese company’s debut in the United Kingdom. A year and a day after launching a range of products in Spain, Xiaomi’s European foray is arriving in the UK, headlined by the Xiaomi Mi 8 Pro Android flagship phone and the opening of an Authorized Mi Store in the Westfield shopping center in London.

    Europe has proven highly receptive to Xiaomi’s charms of high-spec devices at breakthrough prices. The company has 10 stores up and running in Spain, it expanded into France and Italy in May, and now it’s coming to one of the biggest and most hotly contested consumer electronics markets in the region.

    Speaking to The Verge ahead of today’s announcement, Xiaomi... Reported by The Verge 2 hours ago.

    0 0

    DUBLIN (AP) — Ireland brought back all of its big guns to play Argentina at Lansdowne Road on Saturday, and kept Jordan Larmour as fullback.Larmour was one of only three starters retained from the 54-7 beating of Italy in Chicago... Reported by New Zealand Herald 2 hours ago.

    0 0

    Italian police discovered 270 kg (600 lb) of heroin hidden in a container that arrived aboard a ship from Iran, the biggest such haul for at least 20 years in Italy, police said on Thursday. Reported by Reuters 55 minutes ago.

    0 0

    Tottenham are readying an double January swoop on Serie A, while Chelsea are also set to raid with Italy with a €35m midfielder wanted.

    The post Euro Paper Talk: Tottenham in driving seat to land impressive Serie A duo; Chelsea plot €35m midfielder raid appeared first on teamtalk.com. Reported by Team Talk 48 minutes ago.

    0 0

    ROME (AP) — European authorities say they have seized 270 kilograms (595 pounds) of heroin in Genoa's port and allowed part of it to travel on, under police surveillance, to its final destination in the Netherlands where two people... Reported by New Zealand Herald 10 minutes ago.

    0 0

    ROME (AP) — Mario Balotelli has again been left out of the Italy squad, this time for matches against Portugal and the United States.Balotelli was included in Roberto Mancini's first two squads as coach and played his first matches... Reported by New Zealand Herald 11 hours ago.

    0 0

    Sandro Tonali, Vincenzo Grifo and Stefano Sensi have been called up to the Italy squad for the first time. Brescia midfielder Tonali, who only turned 18 in May, has been included on the 27-man list after impressing in Serie B to the extent that he has been compared to Azzurri great Andrea Pirlo. Hoffenheim’s Grifo […]

    The post ´New Pirlo´ Tonali wins first Italy call-up appeared first on Soccer News. Reported by SoccerNews.com 9 hours ago.

    0 0

    Mario Balotelli receives latest Italy snub but 'new Pirlo' Sandro Tonali gets nod Mario Balotelli has again been left out of the Italy squad, this time for matches against Portugal and the United States. Reported by MailOnline 10 hours ago.

    0 0

    ‘Searching for Ingmar Bergman’ Film Review: Margarethe von Trotta Explores Her Love of Swedish Auteur’s Work In the category of culture-driven documentaries that focus on film history, a particularly enjoyable subset of that subset is the kind made by noteworthy artists themselves. There’s Martin Scorsese waxing luxuriously on Italian cinema (“My Voyage to Italy”), Noah Baumbach and Jake Paltrow fanboy-interviewing Brian DePalma for “DePalma,” and now, German filmmaker Margarethe von Trotta (“Hannah Arendt”) taking us on a personal tour of her lifelong admiration for Sweden’s hallowed grandmaster in the playfully inquisitive “Searching for Ingmar Bergman.”

    Von Trotta’s connection to Bergman started when she was a young, New Wave-enamored film lover who responded deeply to his 1957 chess-with-Death masterpiece “The Seventh Seal”; she even opens her valentine of a documentary visiting its famed rocky beach setting, narrating the impact of its establishing shots.

    When she blossomed as an artist herself as part of West Germany’s own exciting crush of post-war filmmaking talent alongside Rainer Werner Fassbinder (for whom she acted) and then-husband Volker Schlöndorff (they made “The Lost Honor of Katharina Blum” together), von Trotta found herself personally acquainted with Bergman after he decamped to Munich in the mid-’70s following a tax evasion charge.

    Bergman even became a fan of her work, including her 1981 feature “Marianne and Juliane” in a list of his favorite movies commissioned by a film festival, the program book for which von Trotta thumbs through for the camera like a kid still in awe of being recognized by so key an influence. (Hey, you would, too, if your movie kept company in a film legend’s consciousness with “Rashomon” and “The Passion of Joan of Arc.”)

    *Also Read:* 'Minding the Gap' Leads All Films in Nominations for Cinema Eye Honors

    It’s von Trotta’s onscreen enthusiasm, too, as she interviews key Bergman collaborators (notable leading ladies Liv Ullmann, Gunnel Lindblom), family (sons Daniel and Ingmar, Jr.), contemporaries (Carlos Saura, Jean-Claude Carrière), and next-generation admirers (Olivier Assayas, Ruben Ostlund, Mia Hansen-Løve), that gives “Searching” its gently thrumming cineaste heart.

    Between the excerpts and analyses, the remembrances, and the honesty that swings from brutal to touching but that is nearly always illuminating, you’ll surely be dipping into the gloom-meister’s oeuvre afterward. (Or maybe shelling out for Criterion’s 39-film Bergman box set, available starting November 20 if you’re likely to be in mourning over the streaming service FilmStruck going away.)

    *Also Read:* 'RBG' and 'Won't You Be My Neighbor?' Among 166 Documentaries Submitted for Oscars

    Bergman’s abiding gift over a career that spanned sixty years — and included successes from “Wild Strawberries” and “Winter Light” through “Scenes from a Marriage” and “Fanny & Alexander” — was a penetrative inventory of the soul as it’s plagued by doubt, loneliness, the existence of God, the vicissitudes of love, and the facing of mortality.

    But to hear those closest to him tell it, Bergman was at heart a wide-eyed child in thrall to the creative process, consumed by the innocence of curiosity and experimentation that keeps all artists in a state of turmoil and evolution. It’s what Ullmann says could turn his being introduced to her, alongside actress/former flame Bibi Andersson on a beach, into the likeness-driven experimental hallmark “Persona,” a life-defining work.

    But at the same time, that ever-nurtured connection to his inner child made Bergman view his own offspring (nine in all, with six women, including Ullmann) as competitors to his creativity. Daniel Bergman, who would direct his father’s screenplay “Sunday’s Children,” jovially notes how dad preferred his own childhood to his own children. In the presence of his kids, we learn, he would openly miss the company of his actors.

    *Also Read:* Terrence Malick to Executive Produce Documentary on Late Rapper Lil Peep

    Elsewhere, his longstanding script supervisor-turned-producer Katinka Farago describes the Bergman who worried he was never good enough, while Assayas succinctly captures how he was a game-changer regarding the psychological, subconscious, and female-centric.

    The most amusing anecdote comes from Bergman’s grandson, who recounts a movie night of “Pearl Harbor” in the home theater in which granddad insisted the projectionist skip anything that wasn’t an action scene. It’s like backhanded proof that with any kind of film, whether an existential drama or slick Hollywood package, Bergman preferred intensity over everything else.

    That von Trotta’s documentary isn’t simply hagiographic keeps it refreshing, although the emphasis on Bergman’s later years, whether lesser works like “The Serpent’s Egg” or his stage directing, also prevents it from potentially satisfying any need to see most of his undisputed classics gone over in detail.

    But with so many documentaries on Bergman already in existence, that von Trotta has made her own uniquely inviting tour of his triumphs, anguishes, and longstanding themes — in essence a roomy portrait of the artist as an engaged, fallible searcher — is its own gift of sorts, from one acolyte of cinema to another.

    

    *Related stories from TheWrap:*

    Stephen Curry and Viola Davis Partner on Charleston Church Shooting Documentary

    Ava DuVernay to Direct Prince Documentary for Netflix

    Sorry, Oscar Documentary Voters: Your Workload Just Doubled

    'Free Solo,' 'Minding the Gap,' 'Won't You Be My Neighbor?' Land IDA Documentary Nominations Reported by The Wrap 3 hours ago.

    0 0

    'New Pirlo' Tonali wins first Italy call-up as Balotelli is snubbed again Roberto Mancini has added three new faces to his squad, with a rising star from Brescia and talented performers from Hoffenheim and Sassuolo selected Reported by Goal.com 9 hours ago.

    0 0

    Amazon strikes deal with Apple to sell new iPhones and iPads Amazon has made a deal with Apple that will see the Cupertino tech company sell its products — including iPhones, iPads, and Apple Watches — directly on Amazon, according to a report from CNET.

    Amazon has sold Apple products before, but those have generally been from third party sellers, which means that prices are often variable (and wildly different from the “official” price that Apple sells them for) and that sourcing isn’t as reputable.

    "Rolling out on Amazon sites in the US, UK, France, Germany, Italy, Spain, Japan, and India over the next few weeks"

    Apple products will start rolling out on Amazon sites in the US, UK, France, Germany, Italy, Spain, Japan, and India over the next few weeks, including both Apple’s devices and those... Reported by The Verge 9 hours ago.

    0 0

    Amazon and Apple have reached an agreement that will see Amazon selling an expanded selection of iPhone, iPad, and Apple Watch devices through its online storefronts in the United States, UK, France, Germany, Italy, Spain, Japan, and India, reports CNET.

    In the near future, Amazon will offer its customers the Apple latest devices, which includes the new 2018 iPad Pro models, the iPhone XR, the iPhone XS and XS Max, Apple Watch Series 4 models, and a selection of Beats headphones. The products will be available through Apple-authorized resellers on Amazon's marketplace.
    Certain Apple products will not be included on Amazon's site, such as the HomePod, which directly competes with Amazon's line of Echo devices.

    In a statement provided to CNET, Amazon said that it added Apple products because it's always aiming to improve the customer experience.

    "Amazon is constantly working to enhance the customer experience, and one of the ways we do this is by increasing selection of the products we know customers want," an Amazon spokesperson said in a statement Friday morning. "We look forward to expanding our assortment of Apple and Beats products globally."

    At the current time, many Apple products are not available on Amazon's site or are sold through unreliable third-party marketplace sellers at non-standard prices. With the new agreement, Apple devices will be available at regular retail prices.

    Independent sellers who offer new and used Apple products on Amazon will have their listings removed after January 4, 2019, under the new deal. Those sellers will need to apply to become Apple authorized resellers on Amazon to continue to offer their wares.

    As CNET points out, while this deal will provide customers with access to a greater selection of Apple products at standard prices, it could potentially impact the used Apple device market on the platform.Tag: Amazon

    Discuss this article in our forums Reported by MacRumours.com 9 hours ago.

    0 0

    The Houston Livestock Show and Rodeo has named the winners of its 2019 Rodeo Uncorked! International Wine Competition.  The competition was held last weekend at NRG Center and featured 3,156 entries from 18 countries, including Argentina, Austria, Chile, France, Italy, Japan, Portugal and South Africa, where the Grand Champion Best of Show hails from. Of those entries, 413 came from Texas wineries, and 370 came from this year’s featured region, California’s Central Coast. Award winners include… Reported by bizjournals 8 hours ago.

    0 0

    *Rome (Italy), 9 November 2018 - **Unilever* and *Bio-on *announce the start of a strategic partnership to develop, produce and sell personal hygiene and care products that guarantee a smaller or no environmental impact. Using patented bio-technologies for natural, biodegradable microplastics production, *Unilever* and *Bio-on* are taking an important step towards building a more sustainable economy and more responsible consumption in the personal care sector.

    This collaboration is designed to meet the demands of consumers, who are increasingly concerned about sustainability and making purchasing choices that respect the environment, whilst making the most of the skills and excellence at both companies.

    *Unilever's* knowledge and large-scale presence on the personal care market with noted brands such as Mentadent, Dove, Zendium, Glysolid, and Sunsilk, teams up with the exclusive know-how of *Bio-on*, the Italian company listed on the AIM segment of Borsa Italiana and specialised in biotechnologies applied to widely used materials, to create completely natural products and solutions.

    “For *Unilever*, developing a partnership with such an excellent Italian company as *Bio-on *is an important step towards the goals we have set ourselves with the Unilever Sustainable Living Plan, primarily to halve the environmental impact of our products by 2030,” claims *Fulvio Guarneri*, Chairman & CEO of Unilever Italia. “This collaboration makes us very proud because it is one of the most important examples through which *Unilever* is making concrete moves towards sustainability in our business strategy.”

    “Research into innovative products and cutting-edge formulations that respect the environment and people is now a priority in the personal care sector,” explains *Marco Astorri*, Chairman and CEO of Bio-on. “We are very pleased to work alongside such a major player as Unilever, with which we will have the great opportunity to introduce real sustainable innovation whilst reaching an increasingly broad consumer base.” *Bio-on* will work with *Unilever* through two new companies, which will focus 100% on exploiting exclusive technologies to develop, produce and supply personal care products.

    *Unilever*

    Unilever is one of the largest companies operating on the Food, Refreshment, Home and Personal Care markets. Located in over 190 countries around the world, its products are used by 2.5 billion consumers every day. Unilever employs approximately 169,000 people worldwide and recorded sales of €52.7 billion in 2016. Approximately 57% of company sales comes from developing countries and emerging markets. The company portfolio includes over 400 brands found in homes all over the world, such as Dove, Sunsilk, Knorr, Algida, Magnum, Lipton, Mentadent, Svelto, and Coccolino. The Unilever Sustainable Living Plan (USLP), outlining the company's sustainable growth plan, has three main goals:

    · Help more than 1 billion people to improve their health and wellbeing by 2020
    · Halve the environmental impact of its products by 2030
    · Improve the living conditions of millions of people by 2020

    The USLP acts as a guide that leads to value creation, boosting growth and trust and cutting risks and costs. The company's sustainable brands are growing 50% more quickly than its other brands and make up approximately 60% of growth recorded by Unilever in 2016.

    In 2017, Unilever came top of the Dow Jones Sustainability Index in its category of reference. The FTSE4Good Index assigned the company the highest score in the Environment category. Unilever has also topped the ranking of Global Corporate Sustainability Leaders for the last seven years, resulting from the research that GlobeScan/SustainAbility runs every year. Finally, Unilever is committed to becoming carbon positive by 2030.

    For further information on Unilever and its brands, visit www.unilever.it.

    For further information on the Unilever Sustainable Living Plan, visit https://www.unilever.it/sustainable-living/*Bio-on *

    Bio-on S.p.A., an Italian Intellectual Property Company (IPC), operates in the bioplastic sector conducting applied research and development of modern bio-fermentation technologies in the field of eco-sustainable and completely naturally biodegradable materials. In particular, Bio-on develops industrial applications through the creation of product characterisations, components and plastic items. Since February 2015, Bio-on S.p.A. has also been operating in the development of natural and sustainable chemicals for the future. Bio-on has developed an exclusive process for the production of a family of polymers called PHAs (polyhydroxyalkanoates) from agricultural waste (including molasses and sugar cane and sugar beet syrups). The bioplastic produced in this way is able to replace the main families of conventional plastics in terms of performance, thermo-mechanical properties and versatility. Bio-on PHAs is a bioplastic that can be classified as 100% natural and completely biodegradable: this has been certified by Vincotte and by USDA (United States Department of Agriculture). The Issuer's strategy envisages the marketing of licenses for PHAs production and related ancillary services, the development of R&D (also through new collaborations with universities, research centres and industrial partners), as well as the realisation of industrial plants designed by Bio-on.

    *Issuer *
    Bio-On S.p.A.
    Via Dante 7/b
    40016 San Giorgio di Piano (BO)
    Phone +39051893001-info@bio-on.it *Nomad**    *
    EnVent Capital Markets Ltd
    25 Savile Row W1S 2ER London
    Tel. +447557879200
    Italian Branch
    Via Barberini, 95 00187 Roma
    Tel: +39 06 896.841 - pverna@envent.it
    *Specialist*
    Banca Finnat Euramerica S.p.A. 
    Piazza del Gesù, 49
    00186 Rome
    Lorenzo Scimia
    Tel: +39 06 69933446 - l.scimia@finnat.it

     

    *Attachment*

    · CS_68_UNILEVER_BIO-ON_E Reported by GlobeNewswire 8 hours ago.

    0 0

    · *Strong USD demand weighs on the EUR/USD pair.*
    · *The selling pressure eases before the pair tests the critical 1.13 mark.*
    · *US Dollar Index looks to close the week around 97.*

    After moving sideways in a relatively tight range near the 1.3150 mark, the EUR/USD pair met a short-lasting selling pressure in the last hour and extended its daily fall to a new 8-day low of 1.1315 before staging a modest rebound. As of writing, the pair was trading at 1.1335, losing 0.25% on a daily basis.

    The pair's recent drop seems to be caused by the end-of-week flows into London fix. With the Fed not voicing any concerns over the recent market volatility and the flattening yield curve in its policy statement yesterday and reassuring the markets that there was no reason to delay the December hike, the US Dollar Index started to erases the losses it suffered following the midterm election outcome. Additionally, today's PPI reading, which showed a higher-than-expected increase in October, provided an additional boost to the buck. At the moment, the index is up 0.27% at 96.90, and not too far away from the weekly high that it set at 97.01 earlier in the session.

    Meanwhile, while speaking to reporters today, Italy's Finance Minister Giovanni Tria reiterated that the key points of their 2019 budget proposal would remain unchanged and that Italy was not the only EU country breaking the EU fiscal rules, to suggest that the Italian budget crisis is not likely to be resolved any time soon. "The Italian coalition was elected to boost the country's struggling economy. Italy's 2018 GDP is 1.13%, the EMU's 2.1%, in 2017 it was 1.45% and 2.38%.  The EU is threatening fines. What is worth more, an extra 0.5% or 1% growth in the  $2.2 trillion Italian economy or EU fines?" said FXStreet senior analyst Joseph Trevisani.

    *Technical levels to watch for*

    1.1300 (October 31 low/Aug. 15 low/2018 low) remains as the next critical support. With a decisive break below that level, the pair could target 1.1235 (Jun. 5, 2017, low) on the downside ahead of 1.1200 (psychological level). Resistances, on the other hand, are located at 1.1400 (20-DMA), 1.1500 (psychological level/Nov. 7 high) and 1.1560 (100-DMA). Reported by FXstreet.com 8 hours ago.

    0 0

    A hundred years ago, Italy's King Vittorio Emanuele III landed in Trieste after a peace treaty with Austria-Hungary was signed. Reported by euronews 7 hours ago.

    0 0

    Reported by RIA Nov. 7 hours ago.

    0 0

    According to analysts from Danske Bank, next week, growth data will be in focus in the Eurozone, where German ZEW and preliminary GDP for Q3 are due to be released. They also point out that Tuesday is the deadline for Italy to send a revised budget to the EU Commission. 

    *Key Quotes: *

    “In the euro area, the *revised HICP and core inflation figures for October are due out on Friday.* The initial estimates were 2.1% y/y and 1.1% y/y for headline and core inflation, respectively, and we do not expect any revisions to these numbers but we will look out for the higher core inflation drivers. 

    “*ZEW figures for November are due on Tuesday. *Current conditions started the year at 95.2 and economic expectations started it at 20.4. In October, these had fallen to 70.1 and -24.7, respectively. In November, we expect some stabilisation of the economic expectations figure, driven not least by the latest signs that a ceasefire in the US-China trade war is becoming more likely. 

    “In* Germany, preliminary Q3 GDP figures are due on Tuesday. *We expect GDP growth to come in at 0.3% q/q. However, we see a significant downside risk to this forecast in light of both falling PMI and Ifo figures and production bottlenecks in the German car sector, which is struggling to adjust to new emissions test procedures.·

    “*On Tuesday, the deadline expires for the Italian government to send a revised budget draft to Brussels.* As market pressure has eased somewhat in recent weeks now ratings decisions are out of the way, our base case is that the government will not comply with the Commission's request. Hence, we believe a further standoff is in store, with the Commission likely to proceed by initiating an excessive deficit procedure against the country.” Reported by FXstreet.com 6 hours ago.

older | 1 | .... | 1053 | 1054 | (Page 1055) | 1056 | 1057 | .... | 1077 | newer